The IPO of Sai Parenterals, a pharmaceutical company, opened for investors on March 24. The company plans to raise ₹409 crore through this issue.
If you are thinking about investing, it is important to understand the company’s business and financial condition.
Strong Interest from Anchor Investors
Before the IPO even opened, big investors showed strong interest. The company raised ₹122 crore from anchor investors at a price of ₹392 per share.
Some well-known investors in this round include Morgan Stanley (Asia), Kotak Mahindra Life Insurance, and Quant Mutual Fund.
Important IPO Details
Opening Date: March 24
Closing Date: March 27
Price Band: ₹372 to ₹392 per share
Issue Type:
Fresh Issue: ₹285 crore
Offer for Sale (OFS): Remaining amount
Lot Size: Minimum 38 shares
Minimum Investment: ₹14,896
Allotment Date: March 30
Listing Date: April 2
What Does the Company Do?
Sai Parenterals is a diversified pharmaceutical company. Its business mainly has two parts:
Branded Generic Medicines
CDMO Services (Contract Development and Manufacturing)
The company develops medicines for both Indian and international markets. It also provides research and manufacturing services to other pharma companies.
Its product range includes:
Injectables
Tablets
Capsules
Ointments
These products are used in areas like:
Cardiovascular diseases
Diabetes (anti-diabetic)
Antibiotics
Dermatology
Use of IPO Funds
The company plans to use the money raised from the IPO for expansion. Its goals include:
Expanding its business globally
Strengthening its formulations business
Increasing manufacturing capacity for injectables and oral solid dosage (OSD)
Growing its presence in regulated markets like Australia and New Zealand
Financial Performance
Sai Parenterals has shown strong growth in recent years.
Revenue increased from ₹967 million in FY 2023 to ₹163 million in FY 2025
Net profit rose from ₹43.7 million in FY 2023 to ₹144 million in FY 2025
For the six months ending September 2025:
Revenue: ₹869 million
Profit: ₹77 million
